Oxolamine
Oxolamine (SKF-9976) is an orally active antitussive. Oxolamine can inhibit CYP2B1/2. Oxolamine has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine increases the AUC of Warfarin and prolongs its terminal half-life. Oxolamine can be used in respiratory disease research[1][2][3][4].
Product Specifications
CAS Number
959-14-8
UNSPSC
12352005
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/oxolamine.html
Smiles
CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1
Molecular Formula
C14H19N3O
Molecular Weight
245.32
References & Citations
[1]Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9 (2) :167-72.|[2]GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.|[3]Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28 (3) :125-33.|[4]Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh) . 1966;24 (2) :286-96.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CYP2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RR208804L4V 200 µL
Mafk (NM_145673) Rat Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 
GTR15201506 1 Vial
Lentiviral mouse Pigo shRNA (UAS) - Lentiviral mouse Pigo shRNA (UAS, iRFP) (25)
Sign In for Pricing
View Details orb775929-01 48 Tests
Human Mannose Receptor C Type 1 (MRC1) ELISA Kit
Sign In for Pricing
View Details orb775929-02 96 Tests
Human Mannose Receptor C Type 1 (MRC1) ELISA Kit
Sign In for Pricing
View Details